Saroj Namrata sold 35,370 shares of OCULAR THERAPEUTIX, INC at $6.55 for −$232k on Nov 5, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Chief Business Officer
Chief Business Officer
Filed Nov 9, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$231,673.50Shares × reported price
Shares traded
35,370Common Stock
Price per share
$6.55Reported price. Read footnotes for ranges.
% of reported position traded
13.82%This security and ownership context
Holdings after
220,522Direct
Trade date
Nov 5, 2026Sell
Filed
Nov 9, 2026, 4:29 PM ET4-day reporting delay
Accession
0001104659-26-124526Code S · Transaction 395957
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 255,892 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

OCUL price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
OCUL · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 16, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago +7.2%1w ago +6.7%1d ago +4.2%
Returns since7d30d90d180d1y

Footnotes in full

F1: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on February 4, 2025, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on November 4, 2026. The sales do not represent a discretionary trade by the reporting person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.4300 to $6.6664, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4 F3: Includes 1,272 shares of common stock acquired under the Corporation's Amended and Restated 2014 Employee Stock Purchase Plan on June 30, 2026.